www.3sbio.com 提示:

本信息仅供医学专业人士参考,如果您是医学专业人士,请点击确定后进入。 如果不是,请点击取消。

取消 确定

3SBio Group has always been committed to solving the problem of
clinical drug use for patients, constantly conquering the challenges
of the disease, using high-quality drugs to improve the quality of
life of patients, and working hard for the benefit of human health.

Cooperation partners

  • Exclusive license for the commercialization of GLP-1 products in China

  • Exclusive license to develop and commercialize programmed therapeutic cells in Greater China

  • Exclusive license for the distribution and promotion of insulin products

  • Collaboration for clinical development and commercialization of MCM1 in China

  • Exclusive partnership to commercialize liposomal products utilizing NanoX™ in Mainland China

  • Priority for potential licensing or development of two ophthalmic-related disease products

  • Exclusive right to develop and commercialize Remitch in China

  • Partnership focused on the development and commercialization of novel bi- and multi-specific antibodies in the field of immuno-oncology

  • Collaboration for clinical development and commercialization of multiple biosimilars in China

  • Potential licensing priorities for four inner ear disease related research products

  • Investment to research and develop early stage cancer drugs